Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: Influence of obesity and smoking

European Journal of Endocrinology

Volumn 160, Issue 3, 2009, Pages 469-480

  Luque Ramírez, Manuel ^a,b   Mendieta Azcona, Covandonga ^c   del Rey Sánchez, Josée M ^a   Matíes, Milagro ^a   Escoba Morreale, Héctor F ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DIANE; DIARIO; FIBRINOGEN; METFORMIN; ORAL CONTRACEPTIVE AGENT; PROTHROMBIN; UNCLASSIFIED DRUG; ANTIANDROGEN; ANTIDIABETIC AGENT; CYPROTERONE ACETATE; ETHINYLESTRADIOL; HOMOCYSTEINE;

ADOLESCENT; ADULT; ARTICLE; BLOOD CLOTTING TEST; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SMOKING; SMOKING CESSATION; THERAPY EFFECT; THROMBOCYTE COUNT; TREATMENT DURATION; WAIST CIRCUMFERENCE; BLOOD; BLOOD CLOTTING; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; THROMBOCYTE; VASCULAR ENDOTHELIUM;

ADULT; ANDROGEN ANTAGONISTS; BLOOD COAGULATION; BLOOD PLATELETS; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL, HORMONAL; CYPROTERONE ACETATE; DRUG COMBINATIONS; ENDOTHELIUM, VASCULAR; ETHINYL ESTRADIOL; FEMALE; FIBRINOGEN; HOMOCYSTEINE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; OBESITY; PARTIAL THROMBOPLASTIN TIME; POLYCYSTIC OVARY SYNDROME; PROTHROMBIN; SMOKING; YOUNG ADULT;

EID: 62649135298     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-08-0725     Document Type: Article

References (58)

1. Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocrine Reviews 2003 24 302-312.
2. Apridonidze T, Essah PA, Iuorno MJ & Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2005 90 1929-1935.
3. Luque-Ramirez M, Alvarez-Blasco F, Botella-Carretero JI, Martinez-Bermejo E, Lasuncion MA & Escobar-Morreale HF. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2007 92 2453-2461.
4. Luque-Ramirez M, Mendieta-Azcona C, Alvarez-Blasco F & Escobar-Morreale HF. Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome. Human Reproduction 2007 22 3197-3203.
5. Talbott EO, Zborowski JV, Rager JR, Boudreaux MY, Edmundowicz DA & Guzick DS. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2004 89 5454-5461.
6. Yildiz BO, Haznedaroglu IC, Kirazli S & Bayraktar M. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. Journal of Clinical Endocrinology and Metabolism 2002 87 3871-3875.
7. Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepard MK & Baron AD. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001 103 1410-1415.
8. Sakkinen PA, Wahl P, Cushman M, Lewis MR & Tracy RP. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. American Journal of Epidemiology 2000 152 897-907.
9. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G & Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Journal of Clinical Investigation 1996 97 2601-2610.
10. Escobar-Morreale HF & San Millan JL. Abdominal adiposity and the polycystic ovary syndrome. Trends in Endocrinology and Metabolism 2007 18 266-272.
11. Alvarez-Blasco F, Botella-Carretero JI, San Millan JL & Escobar-Morreale HF. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Archives of Internal Medicine 2006 166 2081-2086.
12. Jick H, Jick SS, Gurewich V, Myers MW & Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995 346 1589-1593.
13. Sidney S, Petitti DB, Soff GA, Cundiff DL, Tolan KK & Quesenberry CP Jr. Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives. Contraception 2004 70 3-10.
14. Pomp ER, Rosendaal FR & Doggen CJ. Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. American Journal of Hematology 2008 83 97-102.
15. Luque-Ramirez M, Alvarez-Blasco F, Botella-Carretero JI, Sanchon R, San Millan JL & Escobar-Morreale HF. The increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism, and do not result from reduced menstrual losses. Diabetes Care 2007 30 2309-2313.
16. Luque-Ramirez M, Mendieta-Azcona C, Alvarez-Blasco F & Escobar-Morreale HF. Effects of metformin versus ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome. Fertility and Sterility, 2008. In Press, DOI: 10.1016/ j.fertnstert.2008.03.082.
17. Luque-Ramirez M, Alvarez-Blasco F, Uriol Rivera MG & Escobar-Morreale HF. Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin. Human Reproduction 2008 23 1594-1601.
18. Luque-Ramirez M, Alvarez-Blasco F & Escobar-Morreale HF. Antiandrogenic contraceptives increase serum adiponectin in obese polycystic ovary syndrome patients. Obesity 2009 17 3-9.
19. Zawadzki JK & Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In Polycystic Ovary Syndrome, pp 377-387. Eds A Dunaif, JR Givens, FP Haseltine & GR Merriam, Boston: Blackwell Scientific Publications, 1992.
20. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction 2004 19 41-47.
21. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE & Witchel SF. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. Journal of Clinical Endocrinology and Metabolism 2006 91 4237-4245.
22. Escobar-Morreale HF, Sanchon R & San Millan JL. A prospective study of the prevalence of nonclassical congenital adrenal hyperplasia among women presenting with hyperandrogenic symptoms and signs. Journal of Clinical Endocrinology and Metabolism 2008 93 527-533.
23. Luque-Ramirez M, Alvarez-Blasco F, Mendieta-Azcona C, Botella-Carretero JI & Escobar-Morreale HF. Obesity is the major determinant of the abnormalities in blood pressure found in young women with the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2007 92 2141-2148.
24. Clauss A. Gerinnungsphysiologische schnellmethode zur bestimmung des fibrinogens. Acta Haematologica 1957 17 237-246.
25. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK & Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992 340 1111-1115.
26. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J & Vogel R. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. Journal of the American College of Cardiology 2002 39 257-265.
27. Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA & Rodgers GM. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arteriosclerosis and Thrombosis 1993 13 1327-1333.
28. Barrett-Connor E & Khaw KT. Cigarette smoking and increased central adiposity. Annals of Internal Medicine 1989 111 783-787.
29. Canoy D, Wareham N, Luben R, Welch A, Bingham S, Day N & Khaw KT. Cigarette smoking and fat distribution in 21 828 British men and women: a population-based study. Obesity Research 2005 13 1466-1475.
30. Akbartabartoori M, Lean ME & Hankey CR. Relationships between cigarette smoking, body size and body shape. International Journal of Obesity 2005 29 236-243.
31. De Pergola G, De Mitrio V, Giorgino F, Sciaraffia M, Minenna A, Di Bari L, Pannacciulli N & Giorgino R. Increase in both prothrombotic and anti-thrombotic factors in obese premenopausal women: relationship with body fat distribution. International Journal of Obesity and Related Metabolic Disorders 1997 21 527-535.
32. Mertens I & Van Gaal LF. Obesity, haemostasis and the fibrinolytic system. Obesity Reviews 2002 3 85-101.
33. Petitti DB. Oral contraceptives and hypercoagulation. Clinical Advances in Hematology and Oncology 2006 4 813-815.
34. Franks S, Layton A & Glasier A. Cyproterone acetate/ethinyl estradiol for acne and hirsutism: time to revise prescribing policy. Human Reproduction 2008 23 231-232.
35. Seaman HE, de Vries CS & Farmer RD. The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study. Human Reproduction 2003 18 522-526.
36. Diamanti-Kandarakis E, Baillargeon J-P, Iuorno MJ, Jakubowicz DJ & Nestler JE. A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. Journal of Clinical Endocrinology and Metabolism 2003 88 1927-1932.
37. Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H & Tapanainen JS. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. Journal of Clinical Endocrinology and Metabolism 2003 88 148-156.
38. Nader S & Diamanti-Kandarakis E. Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis. Human Reproduction 2007 22 317-322.
39. Wulffele MG, Kooy A, Lehert P, Bets D, Ogterop JC, Borger van der Burg B, Donker AJ & Stehouwer CD. Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial. Journal of Internal Medicine 2003 254 455-463.
40. Vrbikova J, Bicikova M, Tallova J, Hill M & Starka L. Homocysteine and steroids levels in metformin treated women with polycystic ovary syndrome. Experimental and Clinical Endocrinology and Diabetes 2002 110 74-76.
41. Kilicdag EB, Bagis T, Zeyneloglu HB, Tarim E, Aslan E, Haydardedeoglu B & Erkanli S. Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study. Human Reproduction 2005 20 894-899.
42. Carlsen SM, Kjotrod S, Vanky E & Romundstad P. Homocysteine levels are unaffected by metformin treatment in both nonpregnant and pregnant women with polycystic ovary syndrome. Acta Obstetricia et Gynecologica Scandinavica 2007 86 145-150.
43. Pinhas-Hamiel O, Doron-Panush N, Reichman B, Nitzan-Kaluski D, Shalitin S & Geva-Lerner L. Obese children and adolescents: a risk group for low vitamin B12 concentration. Archives of Pediatrics & Adolescent Medicine 2006 160 933-936.
44. Bauman WA, Shaw S, Jayatilleke E, Spungen AM & Herbert V. Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. Diabetes care 2000 23 1227-1231.
45. Zakai NA, Ohira T, White R, Folsom AR & Cushman M. Activated partial thromboplastin time and risk of future venous thromboembolism. American Journal of Medicine 2008 121 231-238.
46. Beckman JA, Goldfine AB, Dunaif A, Gerhard-Herman M & Creager MA. Endothelial function varies according to insulin resistance disease type. Diabetes Care 2007 30 1226-1232.
47. Dunaif A, Wu X, Lee A & Diamanti-Kandarakis E. Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). American Journal of Physiology-Endocrinology and Metabolism 2001 281 E392-E399.
48. Carmassi F, De Negri F, Fioriti R, De Giorgi A, Giannarelli C, Fruzzetti F, Pedrinelli R, Dell'Omo G & Bersi C. Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome. Thrombosis Research 2005 116 207-214.
49. Muniyappa R, Montagnani M, Koh KK & Quon MJ. Cardiovascular actions of insulin. Endocrine Reviews 2007 28 463-491.
50. DeUgarte CM, Bartolucci AA & Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertility and Sterility 2005 83 1454-1460.
51. Baillargeon JP & Nestler JE. Commentary: polycystic ovary syndrome: a syndrome of ovarian hypersensitivity to insulin? Journal of Clinical Endocrinology and Metabolism 2006 91 22-24.
52. Corbould A & Dunaif A. The adipose cell lineage is not intrinsically insulin resistant in polycystic ovary syndrome. Metabolism: Clinical and Experimental 2007 56 716-722.
53. Ketel IJ, Stehouwer CD, Serne EH, Korsen TJ, Hompes PG, Smulders YM, de Jongh RT, Homburg R & Lambalk CB. Obese but not normal-weight women with polycystic ovary syndrome are characterized by metabolic and microvascular insulin resistance. Journal of Clinical Endocrinology and Metabolism 2008 93 3365-3372.
54. Wu FC & von Eckardstein A. Androgens and coronary artery disease. Endocrine Reviews 2003 24 183-217.
55. Littleton-Kearney M & Hurn PD. Testosterone as a modulator of vascular behavior. Biological Research for Nursing 2004 5 276-285.
56. Liang YL, Teede H, Kotsopoulos D, Shiel L, Cameron JD, Dart AM & McGrath BP. Non-invasive measurements of arterial structure and function: repeatability, interrelationships and trial sample size. Clinical Science 1998 95 669-679.
57. Orio F Jr, Palomba S, Cascella T, De Simone B, Manguso F, Savastano S, Russo T, Tolino A, Zullo F, Lombardi G, Azziz R & Colao A. Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. Journal of Clinical Endocrinology and Metabolism 2005 90 6072-6076.
58. Jensterle M, Sebestjen M, Janez A, Prezelj J, Kocjan T, Keber I & Pfeifer M. Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome. European Journal of Endocrinology 2008 159 399-406.